

MENDUS AB (PUBL) HAS DECIDED ON DIRECTED ISSUES OF CLASS C SHARES AND TRANSFER OF OWN ORDINARY SHARES

The board of directors of Mendus AB (publ) ("Mendus") has decided to utilize the authorizations granted by the Annual General Meeting on May 8, 2026, to issue and subsequently immediately repurchase Class C shares in order to facilitate payment of remuneration to board members and bonuses to employees in shares.

In order to offer remuneration to board members and bonuses to employees in shares, as well as to preserve liquidity, the Annual General Meeting on May 8, 2026, authorized the board of directors of Mendus to decide on directed issues of redeemable and convertible Class C shares as well as repurchase of all issued Class C shares through a directed offer to all holders of Class C shares.

Pursuant to the authorizations granted by the Annual General meeting on May 8, 2026, the board has resolved on two directed issues of a total of 2,200,000 Class C shares to DNB Carnegie Investment Bank AB (publ). The subscription price in the directed issues is the quota value of the share, which corresponds to approximately SEK 1 per share. The board has also resolved, pursuant to the authorizations granted by the Annual General Meeting on May 8, 2026, to immediately repurchase all 2,200,000 Class C shares from DNB Carnegie Investment Bank AB (publ) at the same price as the subscription price following completion of the issue of the Class C shares and registration at the Swedish Companies Registration Office.

The Class C shares that are repurchased will be converted into ordinary shares and subsequently transferred to the board members and employees who have chosen to receive their remuneration and bonuses in the form of shares. Payment of bonuses in shares to employees pertains to the financial year 2025 and will be delivered as soon as possible. Payment of remuneration in shares to board members pertains to the current term of office and will be delivered quarterly after the remuneration has been earned.

Mendus already holds 692,554 ordinary shares, but no Class C shares. After the share issue and subsequent conversion of all Class C shares to ordinary shares the total number of ordinary shares in Mendus will amount to 64,784,578.

For more information, please contact:

Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com

About Mendus AB (publ)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving long-term survival for cancer patients, while preserving health and quality of life. We leverage our understanding of dendritic cell biology to develop an advanced clinical pipeline of immunotherapies that combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <https://www.mendus.com/>

Press Release

23 June 2026 23:17:00 CEST



This information is information that Mendus AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2026-06-23 23:17 CEST.